Brokerages Set Humana Inc. (NYSE:HUM) Price Target at $315.33

Shares of Humana Inc. (NYSE:HUM) have earned an average recommendation of “Hold” from the twenty-five ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eighteen have given a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $315.33.

Several equities research analysts have weighed in on the stock. Royal Bank of Canada cut their target price on shares of Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $395.00 price objective on shares of Humana in a research note on Tuesday, October 1st. KeyCorp started coverage on Humana in a research note on Friday, October 11th. They issued a “sector weight” rating for the company. Truist Financial lowered their price target on Humana from $400.00 to $260.00 and set a “hold” rating for the company in a report on Friday, October 11th. Finally, Stephens reiterated an “equal weight” rating and set a $250.00 price objective on shares of Humana in a report on Wednesday, October 9th.

Humana Trading Up 0.8 %

NYSE HUM opened at $260.73 on Tuesday. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. Humana has a 12 month low of $213.31 and a 12 month high of $527.18. The company has a market capitalization of $31.39 billion, a PE ratio of 18.60, a P/E/G ratio of 2.04 and a beta of 0.50. The stock has a 50-day simple moving average of $306.51 and a 200 day simple moving average of $336.35.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. Humana had a return on equity of 16.12% and a net margin of 1.53%. The company had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same period in the prior year, the business posted $8.94 EPS. Humana’s revenue was up 10.4% on a year-over-year basis. Research analysts forecast that Humana will post 16.06 EPS for the current year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 annualized dividend and a yield of 1.36%. Humana’s dividend payout ratio (DPR) is presently 25.25%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Pzena Investment Management LLC raised its position in Humana by 538.7% during the second quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock worth $866,250,000 after acquiring an additional 1,955,375 shares in the last quarter. Ontario Teachers Pension Plan Board lifted its holdings in shares of Humana by 11,647.2% during the first quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock worth $367,342,000 after buying an additional 1,050,459 shares in the last quarter. Marshall Wace LLP boosted its position in shares of Humana by 118.9% in the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock valued at $532,564,000 after acquiring an additional 774,085 shares during the period. International Assets Investment Management LLC increased its position in Humana by 261,025.1% during the third quarter. International Assets Investment Management LLC now owns 738,984 shares of the insurance provider’s stock worth $2,340,660,000 after acquiring an additional 738,701 shares during the period. Finally, Steadfast Capital Management LP acquired a new stake in Humana in the 1st quarter worth about $158,813,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.